

Hwan Geun Choi, Ph.D

Position: CEO
 Department:
 Affiliation: B2SBio
 Office: +82-32-245-1041
 E-mail: hwangeun@b2sbio.com
 Homepage: <https://voronoi.io/ko/>

**Education**

2008.03-2011.02	Ph.D	Sogang University
1998.09-2008.08	MS	Sogang University
1993.02-1998.08	BS	Sogang University

Professional Experience

2018.06-current	CEO	B2SBio
2014.06-2018.06	Principal Researcher	Daegu-Gyeongbuk Medical Innovation Foundation
2011.03-2014.05	Research Scientist	Dana Farber Cancer Institute
2008.04-2011.02	Research Associate	Korea Institute of Science and Technology
2006.06-2008.04	Research Associate	Dana Farber Cancer Institute
2000.07-2006.04	Scientist	LG Life Sciences

Academic Society

2019.01-current	Member	The Pharmaceutical Society of Korea
2022.01-current	Member	Korean Chemical Society
2020.01-current	Member	American Association for Cancer Research

Publications

Discovery of a potent dual ALK and EGFR T790M inhibitor, Jang, Jaebong; Son, Jung Beom; To, Ciric; Bahcall, Magda; Kim, So Young; Kang, Seock Yong; Mushajiang, Mierzhati; Lee, Younho; Janne, Pasi A.; **Choi, Hwan Geun***; Gray, Nathanael S.*, *European Journal of Medicinal Chemistry* (2017), 136, 497-510.

Suppression of the metastatic spread of breast cancer by DN10764 (AZD7762)-mediated inhibition of AXL signaling, Joon-Suk Park, ChuHee Lee, Hyun-Kyoung Kim, Dayea Kim, Jung Beom Son, Eunhwa Ko, Joong-Heui Cho, Nam-Doo Kim, Hong-Yan Nan, Choong-Yong Kim, Sukkyoon Yoon, Sun-Hwa Lee*, **Hwan Geun Choi***, *Oncotarget*, (2016) 7(50):83308-83318.

EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors, Ercan, Dalia[#], **Choi, Hwan Geun[#]**; Yun, Cai-Hong; Capelletti, Marzia; Xie, Ting; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A. *Clinical Cancer Research* (2015), 21(17), 3913-3923.

Brain Penetrant LRRK2 Inhibitor **Hwan Geun Choi**, Jinwei Zhang, Xianming Deng, John M. Hatcher, Matthew P. Patricelli, Zheng Zhao, Dario R. Alessi* and Nathanael S. Gray*, *ACS Medicinal Chemistry Letters*, (2012), 3(8), 658-662